Is AbbVie Stock a Buy?
20/4 14:15
It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to failed its clinical trials. Investors are also on edge over how the Trump administrat...